此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Skills Based Counseling for Adherence and Depression in HIV+ Methadone Patients - 1

2017年12月7日 更新者：Steven A. Safren、Massachusetts General Hospital

CBT for Depression & Adherence in HIV Methadone Patients

Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001).

Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.

研究概览

地位

完全的

条件

干预/治疗

详细说明

Symptoms of depression (i.e. low motivation, poor concentration, loss of interest, sad mood, suicidal ideation) that occur in the context of substance abuse or dependence can interfere with self-care behaviors necessary for maintaining HIV care, as well as interfere with potential benefit from an intervention that focuses on adherence alone. We hypothesize that teaching skills to cope with depression will improve the outcome from an adherence intervention to promote healthier living with HIV, in HIV+ opioid dependent individuals in methadone maintenance treatment.

Overview of Research Plan. Patients who are HIV positive and who are receiving methadone maintenance for opioid dependence will be randomized to treatment with either: (1) CBT, a combination of CBT for depression and HIV medication adherence, including a single session intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction with physician feedback regarding baseline study assessments or (2) the single session intervention for HIV medication adherence (Life-Steps, Safren et al., 2001) in conjunction with physician feedback regarding baseline study assessments. Participants will be followed for one-year post-randomization.

研究类型

介入性

注册 (实际的)

89

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Massachusetts General Hospital

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • HIV seropositive
  • Currently enrolled in methadone maintenance treatment for at least one month
  • Current major or subsyndromal depression (subsyndromal depression is defined by major depression that does not meet full diagnostic criteria but with a clinical global impression of severity (CGI-S) of 2 (mildly ill))
  • Is prescribed antiretroviral therapy for HIV and therefore under the care of a primary care provider.
  • Between the ages of 18 and 65.

Exclusion Criteria:

  • Active untreated, unstable, major mental illness (i.e., untreated psychosis or mania), or other Axis I psychiatric disorders (other than depression) that would interfere with the ability to participate (i.e. CGI-S >6)
  • Unable or unwilling to provide informed consent.
  • Currently in cognitive behavioral therapy for depression.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：单身的

武器和干预

参与者组/臂
干预/治疗
实验性的：CBT-AD
Cognitive behavioral therapy for adherence and depression
行为的：CBT-AD
Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
有源比较器：ETAU
Enhanced treatment as usual
行为的：ETAU
Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Percent Medication Adherence at 3-month Follow-up Assessment
大体时间：3-month assessment
Post-treatment assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
3-month assessment
Percent Medication Adherence at 12-month Follow-up Assessment
大体时间：12-month follow-up assessment
Follow-up assessment in adherence to HIV medication. Doses taken were assessed by downloading information from the electronic pill cap and corroborated by participant self-report. Adherence was calculated as the number of doses taken over the time period divided by the number of doses prescribed.
12-month follow-up assessment

次要结果测量

结果测量
措施说明
大体时间
Clinician-assessed Depression Rating at 3 Month Follow-up Assessment
大体时间：3 month follow-up
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
3 month follow-up
HIV Viral Load at 12-month Follow-up Assessment
大体时间：12-month follow-up assessment
HIV plasma RNA (log HIV viral load)at the 12-month follow-up assessment.
12-month follow-up assessment
CD4+ Lymphocyte Count at 12-month Follow-up Assessment.
大体时间：12-month follow-up assessment
CD4+ lymphocyte cell count at 12-month follow-up assessment.
12-month follow-up assessment
Clinician-assessed Depression at 12-month Follow-up Assessment
大体时间：12-month follow-up assessment
Depression was assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) by a clinical interviewer blind to participants' study condition. The scale ranges from 0 to 60 with 7-19 indicating mild depression and 20-34 indicating moderate depression.
12-month follow-up assessment
HIV Viral Load at 3-month Follow-up Assessment
大体时间：3-month assessment
HIV plasma RNA (log HIV viral load)at the 3-month follow-up assessment.
3-month assessment
CD4+ Lymphocyte Count at 3-month Follow-up Assessment.
大体时间：3-month assessment
CD4+ lymphocyte cell count at 3-month follow-up assessment.
3-month assessment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Massachusetts General Hospital

合作者

National Institute on Drug Abuse (NIDA)

调查人员

  • 首席研究员：Steven Safren, Ph.D.、Massachusetts General Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2005年2月1日

初级完成 (实际的)

2009年7月1日

研究完成 (实际的)

2009年7月1日

研究注册日期

首次提交

2005年9月20日

首先提交符合 QC 标准的

2005年9月20日

首次发布 (估计)

2005年9月22日

研究记录更新

最后更新发布 (实际的)

2018年1月2日

上次提交的符合 QC 标准的更新

2017年12月7日

最后验证

2017年12月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • NIDA-18603-1
  • R01DA018603 (美国 NIH 拨款/合同)

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅